A randomized phase II trial of 5-day versus 10-day schedules of decitabine in older patients with newly diagnosed acute myeloid leukemia

BACKGROUND: Hypomethylating agents such as decitabine are standard of care for older patients with newly diagnosed acute myeloid leukemia. Single-arm studies have suggested that a 10-day schedule of decitabine may result in better outcomes than the standard 5-day schedule. The aim of this study was...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Lancet Haematol
Main Authors: Short, Nicholas J., Kantarjian, Hagop M., Loghavi, Sanam, Huang, Xuelin, Qiao, Wei, Borthakur, Gautam, Kadia, Tapan M., Daver, Naval, Ohanian, Maro, Dinardo, Courtney D., Estrov, Zeev, Kanagal-Shamanna, Rashmi, Maiti, Abhishek, Benton, Christopher B., Bose, Prithviraj, Alvarado, Yesid, Jabbour, Elias, Kornblau, Steven M., Pemmaraju, Naveen, Jain, Nitin, Gasior, Yvonne, Richie, Mary Ann, Pierce, Sherry, Cortes, Jorge, Konopleva, Marina, Garcia-Manero, Guillermo, Ravandi, Farhad
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6563344/
https://ncbi.nlm.nih.gov/pubmed/30545576
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S2352-3026(18)30182-0
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados